As of Jan 20
| +0.18 / +1.93%|
The 2 analysts offering 12-month price forecasts for Novelion Therapeutics Inc have a median target of 13.63, with a high estimate of 13.75 and a low estimate of 13.50. The median estimate represents a +43.42% increase from the last price of 9.50.
The current consensus among 3 polled investment analysts is to Hold stock in Novelion Therapeutics Inc. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.